In 2017, health care costs accounted for 17% of American economic output. Largely driven by a rise in the cost of prescription drugs, this was up from 14.5% in 2003. Now, large pharmaceutical companies and start-ups alike are pursuing the development of "biosimilar" drugs which have been shown to provide significant cost savings to consumers. Read the full article from The Economist using the link below.